Hypoxia-inducible factor (HIF)-1α plays a key role in hypoxic adaptation of tumor cells. Overexpression of HIF-1α is associated with tumor aggressiveness and worse prognosis in several malignancies. Presumably, expression of HIF-1a may be reflected by positron emission tomography with 2-deoxy-2 [fluorine-18] fluoro-D-glucose (18F-FDG PET). There are inconsistent data about relationships between FDG PET and HIF-1α.
Purpose
To provide evident data about associations between maximum standardized uptake value (SUVmax) and HIF-1α expression in solid tumors.
Material and Methods
MEDLINE, SCOPUS, and EMBASE databases were screened for relationships between SUV and HIF-1α up to August 2019. Overall, 21 studies with 1154 patients were identified. The following data were extracted from the literature: authors; year of publication; number of patients; and correlation coefficients.
Results
Correlation coefficients between SUVmax and HIF-1α were in the range of −0.51–0.71. The pooled correlation coefficient was 0.27 (95% confidence interval [CI] = 0.14–0.41). Furthermore, correlation coefficients for some tumor entities were calculated. For this sub-analysis, data for primary tumors with >2 reports were included. The calculated correlation coefficients in the analyzed subgroups were as follows: head and neck squamous cell carcinoma: ρ = 0.25 (95% CI = 0.07–0.42); non-small lung cell cancer: ρ = 0.27 (95% CI = −0.14–0.67); uterine cervical cancer: ρ = −0.09 (95% CI = −0.89–0.71); thymic tumors: ρ = 0.39 (95% CI = 0.04–0.58).
Conclusion
SUVmax of FDG PET correlated weakly with expression of HIF-1α both in overall sample and tumor subgroups. Therefore, FDG PET cannot be used for prediction of hypoxia in clinical practice.
KitajimaKMiyoshiYYamanoT, et al.
Prognostic value of FDG-PET and DWI in breast cancer. Ann Nucl Med2018;
32:44–53.
2.
LiSJGuoWRenGXHuangG, et al.
Expression of Glut-1 in primary and recurrent head and neck squamous cell carcinomas, and compared with 2-[18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg2008;
46:180–186.
3.
MiccòMVargasHABurgerIA, et al.
Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol2014;
83:1169–1176.
4.
VeraPDubrayBPalieO, et al.
Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. EJNMMI Res2014;
4:12.
5.
AbgralRKeromnesNRobinP, et al.
Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging2014;
41:659–667.
6.
Surov A, Meyer HJ, Wienke A. Standardized uptake values derived from 18F-FDG PET may predict in lung cancer microvessel density and expression of KI 67, VEGF, and HIF-1αα but not expression of cyclin D1, PCNA, EGFR, PD L1 and p53. Contrast Media Mol Imaging 2018; Article ID 9257929. DOI: 10.1155/2018/9257929
7.
Surov A, Meyer HJ, Wienke A. Can Imaging Parameters provide information regarding histopathology in head and neck squamous cell carcinoma? A Meta-Analysis. Transl Oncol 2018;11:498–503.
8.
CochetAPigeonnatSKhouryB, et al.
Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors. J Nucl Med2012;
53:512–520.
9.
AlbadariNDengSLiW.The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov2019;
14:667–682.
10.
GongLZhangWZhouJ, et al.
Prognostic Value of HIFs Expression in Head and Neck Cancer: A Systematic Review. PLoS One2013;
8:e75094.
11.
HuangMChenQXiaoJ, et al.
Overexpression of hypoxia-inducible factor-1α is a predictor of poor prognosis in cervical cancer: a clinicopathologic study and a meta-analysis. Int J Gynecol Cancer2014;
24:1054–1064.
12.
RenWMiDYangK, et al.
The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis. Swiss Med Wkly2013;
143:w13855.
13.
FurukawaTMiyataYKushitaniK, et al.
Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer. Jpn J Clin Oncol2015;
45:1154–1161.
14.
GrönroosTJLehtiöKSöderströmKO, et al.
Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer2014;
14:876.
15.
HanMWLeeHJChoKJ, et al.
Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head Neck2012;
34:1395–1402.
16.
JoMSChoiOHSuhDS, et al.
Correlation between expression of biological markers and [F]fluorodeoxyglucose uptake in endometrial cancer. Oncol Res Treat2014;
37:30–34.
17.
KairaKShimizuKKitaharaS, et al.
2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. Eur J Cancer2018;
101:181–190.
18.
KairaKMurakamiHEndoM, et al.
Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Res2013;
33:4219–4228.
19.
KairaKEndoMAbeM, et al.
Biologic correlates of 18F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer2011;
71:144–150.
20.
KairaKEndoMAbeM, et al.
Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol2010;
28:3746–3753.
21.
KairaKSerizawaMKohY, et al.
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer2012;
48:1244–1254.
22.
KairaKAbeMNakagawaK, et al.
18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study. Eur J Radiol2012;
81:2423–2429.
23.
KairaKSerizawaMKohY, et al.
Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer2014;
83:197–204.
24.
MiyawakiAIkedaRHijiokaH, et al.
SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma. Oncol Rep2010;
23:1205–1212.
25.
NorikaneTYamamotoYMaedaY, et al.
Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. Nucl Med Commun2014;
35:30–35.
26.
ParkSISuhDSKimSJ, et al.
Correlation between biological marker expression and F-fluorodeoxyglucose uptake in cervical cancer measured by positron emission tomography. Onkologie2013;
36:169–174.
27.
ShimomuraHSasahiraTYamanakaY, et al. [
18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma. Int J Clin Oncol2015;
20:308–316.
28.
Surov A, Meyer HJ, Hölhn AK, et al. Associations between 18F-FDG-PET and complex histopathological parameters including tumor cell count and expression of KI 67, EGFR, VEGF, HIF-1α and p53 in head and neck squamous cell carcinoma. Mol Imaging Biol 2019;21:368–374.
29.
Surov A, Meyer HJ, Höhn AK, et al. Metabolo-volumetric parameters of 18F-FDG-PET can predict expression of EGFR and HIF 1alpha in uterine cervical cancer. Cancer Biomark 2019;24:135–140.
30.
TakebayashiRIzuishiKYamamotoY, et al.
[18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer.J Exp Clin Cancer Res2013;
32:34.
31.
TobaHKondoKSadoharaY, et al.
18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg2013;
44:e105–112.
32.
YamadaTUchidaMKwang-LeeK, et al.
Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas.Oral Surg Oral Med Oral Pathol Oral Radiol2012;
113:464–471.
33.
ZhaoKYangSYZhouSH, et al.
Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxia-inducible-factor-1α and the phosphoinositide 3-kinase/protein kinase B pathway. Oncol Lett2014;
7:984–990.
34.
MoherDLiberatiATetzlaffJ, et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009;
6:e1000097.
35.
WhitingPFRutjesAWWestwoodME, et al.
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med2011;
155:529–536.
36.
LeeflangMMDeeksJJGatsonisC, et al.
Systematic reviews of diagnostic test accuracy. Ann Intern Med2008;
149:889–897.
37.
ZamoraJAbrairaVMurielA, et al.
Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol2006;
6:31.
38.
DerSimonianRLairdN.Meta-analysis in clinical trials. Control Clin Trials1986;
7:177–188.
39.
OsinskySZavelevichMVaupelP.Tumor hypoxia and malignant progression. Exp Oncol2009;
31:80–86.
40.
RuanKSongGOuyangG.Role of hypoxia in the hallmarks of human cancer. J Cell Biochem2009;
107:1053–1062.
41.
DenkoNC.Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer2008;
8:705–713.
